Click here for The Motley Fool’s resources on Coronavirus and the market. Patients are better off using pharmaceutical CBD than artisanal forms. Cannabidiol (CBD) — an active compound in cannabis — has attracted a lot of attention in recent years for its purported health benefits, but the medical research about just what those benefits may…
Click here for The Motley Fool’s resources on Coronavirus and the market.
Cannabidiol (CBD)– an active compound in cannabis– has brought in a great deal of attention recently for its supposed health advantages, however the medical research study about simply what those benefits might be is still ongoing. Up until now, the clearest evidence that CBD has actually helped patients has come from its use as an anti-seizure treatment for youths with specific kinds of epilepsy.
Now, a research study conducted out of the Children’s National Medical facility in Washington, D.C., has actually found that not all types of CBD work the same way. “Our research study shows that pharmaceutical CBD might undoubtedly be more effective than artisanal CBD,” says the study’s lead author, Dr. Nathan T. Cohen.
Artisanal products contain differing concentrations of CBD, and also consist of tetrahydrocannabinol (THC)– the psychedelic compound in marijuana. Pharmaceutical CBD, by contrast, contains no THC. In a study on kids with epilepsy, those who used artisanal CBD in fact saw a 70% increase in seizures while those who utilized pharmaceutical CBD had a 39line in seizures.
While Cohen discovered the outcomes worrying, “since lots of individuals continue to utilize artisanal CBD,” the research study was fairly little, with simply 31 children and teens getting involved. In addition, 11 of the individuals experienced side impacts, and all were amongst the group utilizing pharmaceutical CBD.
Image source: Getty Images.
Strong demand for CBD-based medicines
Cannabis– based medicines are still a rarity in the U.S.– the Fda (FDA) has so far just authorized Epidiolex, a drug made by GW Pharmaceuticals ( NASDAQ: GWPH), for the treatment of particular seizures.
The company’s year-end outcomes, launched on Feb. 25, showed Epidiolex sales reaching $2964 million throughout the drug’s first complete year on the marketplace. GW expects more development in 2020 as it released Epidiolex commercially in Germany in Q4 2019 and prepares to release it in the U.K., Spain, France, and Italy this year.
Shares of GW are down more than 42%over the previous year, but that’s much better than the 67Þcline that the Horizons Marijuana Life Sciences ETF has actually experienced during the same duration.
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>
position in any of the stocks discussed. The Motley Fool has no position in any of the stocks mentioned.
The Motley Fool has a disclosure policy“>